Dong-E-E-Jiao Co Ltd
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
203 / 1328
Position in country
1453 / 7387
Return on Assets, %
8.9
-2.7
Net income margin, %
24.3
2.8
EBITDA margin, %
30.4
10.8
Debt to Equity, %
0.4
19.2
Intangible assets and goodwill, %
2.4
3.6
Revenue CAGR 3Y, %
11.4
8.5
Total Equity change 1Y, %
0.8
0
Revenue Y, % chg
10.9
0.5
P/E
36.6
22.7
P/BV
3.9
1.5
P/S
8.9
2.3
EV/S
7.1
2.4
EV/EBITDA
27.9
7.4
Average Analyst recommendation
Buy
Buy
Average upside forecasts, %
2.7
51.3
Forward P/E
29.1
15.6
Dividend Yield, %
1.7
1.7
Forward Dividend Yield, %
0.3
0.2
Expected dividend per share
0.2
0
Payout Ratio, %
99.6
30.3
Competitors
Ranks
-
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
00%
-
CSPC Pharmaceutical Group Ltd
00%
-
Dong-E-E-Jiao Co Ltd
00%
-
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
00%
-
Beijing Tongrentang Co Ltd
00%
-
Yunnan Baiyao Group Co Ltd
00%
-
Hansoh Pharmaceutical Group Company Ltd
00%
-
Zhejiang Nhu Co Ltd
00%
-
Jiangsu Hengrui Pharmaceuticals Co Ltd
00%
-
Shanghai Fosun Pharmaceutical Group Co Ltd
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
China
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals
Sub-sector
Health Care
Capitalization (millions of $)
5828.2
Ticker
000423.SZ
ISIN
CNE0000006Y9
IPO date
1996-07-29
Availability on Russian exchanges
No
Reporting for
2024-03-21
Date fact. publication of reports
2023-12-31
Company Description
Dong-E-E-Jiao Co., Ltd., formerly SHAN DONG DONG-E E-JIAO CO., LTD, is a China-based company principally engaged in the research, development, production and sale of traditional Chinese medicines of Ejiao and Ejiao series products. The Company distributes its Ejiao and Ejiao series products under the brand name of Dong-E E-Jiao. The Company is also involved in the production and sale of medical instrument and pharmaceutical excipients, as well as pharmaceutical trading business. The Company operates its business in domestic market, with East China and South China as its main markets.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: